Inspiromatic-safety and efficacy study of a new generation dry powder inhaler in asthmatic children

2018 ◽  
Vol 53 (10) ◽  
pp. 1348-1355 ◽  
Author(s):  
Guy Steuer ◽  
Dario Prais ◽  
Huda Mussaffi ◽  
Meir Mei-Zahav ◽  
Ophir Bar-On ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Efficacy Study ◽  
Dry Powder ◽  
Safety And Efficacy ◽  
Asthmatic Children ◽  
New Generation

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults

2004 ◽  
Vol 20 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Edwin A. Bronsky ◽  
Jay Grossman ◽  
Marc J. Henis ◽  
Paul P. Gallo ◽  
Ümit Yegen ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Asthmatic Children

scholarly journals Clinical effect of Diskus™ dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children

1998 ◽  
Vol 11 (2) ◽  
pp. 350-354 ◽  
Author(s):  
K. G. Nielsen ◽  
I. L. Auk ◽  
K. Bojsen ◽  
M. Ifversen ◽  
B. Klug ◽  
...  
Keyword(s):  
Clinical Effect ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Asthmatic Children

scholarly journals Mometasone furoate dry powder inhaler for the treatment of asthma

2012 ◽  
Vol 9 (4) ◽  
pp. 79-87
Author(s):  
A V Emelyanov ◽  
L A Goryachkina
Keyword(s):  
Antiinflammatory Activity ◽  
Dry Powder Inhaler ◽  
Persistent Asthma ◽  
Mometasone Furoate ◽  
Inhaled Corticosteroid ◽  
Dry Powder ◽  
Safety And Efficacy ◽  
Therapeutic Choice ◽  
Efficacy Profile

The review is focused on inhaled mometasone furoate (Asmanex Twisthaler), a new medication for the treatment of asthma in adults and childred (12 years and older). Mometasone furoate (MF) has high antiinflammatory activity and low systemic bioavalability. MF has an excellent safety and efficacy profile in approved doses 200—800 mcg/daily od (in the evening) or bid (in the morning and in the evening). For patients with persistent asthma required treatment with an inhaled corticosteroid, MF is an excellent therapeutic choice.

Eformoterol TurbohalerR compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids

2004 ◽  
Vol 15 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Paul Everden ◽  
Malcolm Campbell ◽  
Chris Harnden ◽  
Hugh McGoldrick ◽  
Bavesh Bodalia ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Dry Powder Inhaler ◽  
Dry Powder ◽  
Asthmatic Children

A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness

2021 ◽  
Vol 42 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Donald P. Tashkin ◽  
Arkady Koltun ◽  
Róisín Wallace
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Fluticasone Propionate ◽  
Healthy Volunteers ◽  
Pulmonary Disease ◽  
Dry Powder Inhaler ◽  
Chemical Degradation ◽  
Chronic Obstructive ◽  
Dry Powder ◽  
Obstructive Pulmonary Disease ◽  
Flow Rates

Background: A generic combination of fluticasone propionate and salmeterol xinafoate inhalation powder in a premetered, multidose, nonreusable inhaler was recently approved. Objective: To assess the performance of the generic device. Methods: Findings from three studies with regard to device usability, function, and robustness were reviewed. Results: In a study to assess device function in patients and healthy volunteers, the generic device was successfully used by patients with asthma and chronic obstructive pulmonary disease who were either dry powder inhaler users or dry powder inhaler‐naive, even though they were not trained beyond being provided the instructions for use. In a study to measure inhaled flow rates generated by patients and healthy volunteers, the generic device consistently simulated the delivery of a full dose of drug, even to patients with severe respiratory disease and reduced inspiratory flow rates. Although the generic device had a slightly higher airflow resistance, this study demonstrated that this difference did not result in any clinically meaningful differences in terms of drug delivery. Pressure drop, a key parameter that drives the fluidization and aerosolization of the powder dose, was found to be comparable between the devices. In an open-label study, the generic device met all U.S. Food and Drug Administration specifications for device robustness after 21.5 days of twice-daily dosing via oral inhalation among 111 participants with asthma or chronic obstructive pulmonary disease. All inhalers tested demonstrated conformity with a pharmacopeia with respect to key quality parameters (assay, delivered dose uniformity, aerodynamic size distribution). There was no evidence of chemical degradation of the active ingredients, nor of microbial or water ingress into the powder, as a result of inhaler use.

Sign in / Sign up

Export Citation Format

Share Document